What's the response rate for ruxolitinib plus azacitidine?

The answer isn’t a single number, because the “response rate” for ruxolitinib plus azacitidine depends on the disease setting and how response is defined. Here’s a quick, practical snapshot:

- Disease contexts studied together include higher‑risk myelodysplastic syndromes (MDS) and MDS/MPN (and sometimes related myeloid neoplasms).
- Reported activity in early‑phase studies has generally shown:
- Overall response rate (ORR, including CR/PR/hematologic improvement [HI]) roughly in the 30%–60% range, depending on the trial and criteria used.
- Complete remission (CR) rates tend to be lower, often in the ~5%–20% range.
- Hematologic improvement (HI) can be a meaningful portion of responders, sometimes in the 20%–40% range.
- Important caveats: these are small, nonrandomized studies with varying definitions (e.g., IWGM or other criteria), and cytopenias or infections can be more common with the combo.

If you can specify:
- the exact disease (e.g., higher‑risk MDS, MDS/MPN, CMML, AML in a specific setting),
- the particular trial or publication you have in mind, and
- whether you want ORR, CR, PR, or HI numbers,

I can pull the precise figures from that study. Also, if you’d like, I can summarize the key trials and their reported response rates.